Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT331 in Healthy Women and Women With Bacterial Vaginosis
NCT06469164Phase 1Completed
- Sponsor
- BioNTech SE
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BNT331 in bacterial vaginosis (BV) (7 arms), sponsored by BioNTech SE. Primary endpoint: Treatment-Emergent Adverse Events at 120 days. Started Jul 2024; status: completed.
02
Drugs
BNT331
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT06469164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06469164.